Home›Trial›NCT05453903
🔬NCT05453903Phase 1ACTIVE NOT RECRUITING

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Study Summary

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).

Conditions
Leukemia, Myeloid, Acute
Interventions / Drugs
BleximenibVenetoclax (VEN)Azacitidine (AZA)CytarabineDaunorubicin or Idarubicin
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment196 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.551002+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.